companies

Sooma

Founded 2013
Employees 10+
Primary contact
Atomitie 5 C
00370 Helsinki
Finland
+358 10 328 9811
Links
https://soomamedical.com/
Diseases & Conditions
Sections
Sooma is developing, manufacturing, and marketing non-invasive therapy devices that use transcranial direct current stimulation (tDCS) technology to treat neurological and psychiatric disorders (depression and chronic pain). The company's first product is the first portable device approved for treating major depressive disorder (MDD). In 2017, Sooma launched another brain stimulation treatment, Sooma Pain Therapy, for chronic pain — offering opiate-free pain relief for fibromyalgia and chronic neuropathic pain.  
Founded 2013
Employees 10+
Primary contact
Atomitie 5 C
00370 Helsinki
Finland
+358 10 328 9811
Links
https://soomamedical.com/
Diseases & Conditions
Sections

Funding 💰

Total €2.5M
Select investors Lifeline Ventures, Innovestor, Finnvera, Italian Angels for Growth (IAG), Athensmed

Key people 🧑‍🤝‍🧑

Highlights ⭐

  • Solving the problem: According to the WHO, depression is one of the leading causes of disability worldwide, affecting approximately 264 million people of all ages, but more often young adults aged 18-25. It is estimated that the cost of this disease is $1 trillion (USD) per year. 🔗
  • It works: Sooma's technology is trusted by over 100 clinics, universities and hospitals all around the world. As of May 2023, over 3,000 patients in more than 30 countries have found relief with Sooma treatments.
  • Ready for the U.S. market: In March 2023, Sooma was granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) for its portable, patient-administered neuromodulation device to treat depression. The FDA's breakthrough designation is reserved for novel therapies that show significant potential to provide a substantial improvement over existing options for severe or life-threatening conditions. 🔗

Video ▶️

Quotes 💬

“
I'm very happy for the possibility to invest in Sooma. As a medical doctor I see the urgent need for Sooma's product. As an investor, I'm happy for the strong development of the company and great steps in building international sales.
— Kustaa Piha, CEO and investor of Athensmed 🔗
“
We have been impressed by the efficacy shown by Sooma in clinical practice and are very happy to invest in a non-invasive, drug-free solution for treating depression. This is the thirteenth foreign investment by the members of Italian Angels for Growth and is a strong indication of the world-class level of the management team in Sooma.
— Michele Marzola and Carlo Brunetti, IAG members 🔗
Last update: May 23, 2023